188 related articles for article (PubMed ID: 10067675)
1. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.
Barchfeld GL; Hessler AL; Chen M; Pizza M; Rappuoli R; Van Nest GA
Vaccine; 1999 Feb; 17(7-8):695-704. PubMed ID: 10067675
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
[TBL] [Abstract][Full Text] [Related]
3. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
[TBL] [Abstract][Full Text] [Related]
4. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine.
Cusi MG; Lomagistro MM; Valassina M; Valensin PE; Glück R
Vaccine; 2000 Jun; 18(25):2838-42. PubMed ID: 10812227
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
[TBL] [Abstract][Full Text] [Related]
6. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.
Goff PH; Eggink D; Seibert CW; Hai R; Martínez-Gil L; Krammer F; Palese P
PLoS One; 2013; 8(11):e79194. PubMed ID: 24223176
[TBL] [Abstract][Full Text] [Related]
7. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.
Haan L; Verweij WR; Holtrop M; Brands R; van Scharrenburg GJ; Palache AM; Agsteribbe E; Wilschut J
Vaccine; 2001 Apr; 19(20-22):2898-907. PubMed ID: 11282201
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus.
Lei H; Peng X; Shu H; Zhao D
J Med Virol; 2015 Jan; 87(1):39-44. PubMed ID: 24861477
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
[TBL] [Abstract][Full Text] [Related]
11. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.
Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K; Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T
Vaccine; 1994 Sep; 12(12):1083-9. PubMed ID: 7998417
[TBL] [Abstract][Full Text] [Related]
12. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
14. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
Tumpey TM; Renshaw M; Clements JD; Katz JM
J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.
Barackman JD; Ott G; O'Hagan DT
Infect Immun; 1999 Aug; 67(8):4276-9. PubMed ID: 10417205
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study.
Pan SC; Hsu WT; Lee WS; Wang NC; Chen TJ; Liu MC; Pai HC; Hsu YS; Chang M; Hsieh SM
Vaccine; 2020 Jan; 38(5):1048-1056. PubMed ID: 31812463
[TBL] [Abstract][Full Text] [Related]
17. Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.
Zhou F; Goodsell A; Uematsu Y; Vajdy M
Clin Vaccine Immunol; 2009 Apr; 16(4):471-8. PubMed ID: 19193829
[TBL] [Abstract][Full Text] [Related]
18. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
Tamura SI; Kurata T
Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63).
Pine S; Barackman J; Ott G; O'Hagan D
J Control Release; 2002 Dec; 85(1-3):263-70. PubMed ID: 12480330
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults.
Boyce TG; Hsu HH; Sannella EC; Coleman-Dockery SD; Baylis E; Zhu Y; Barchfeld G; DiFrancesco A; Paranandi M; Culley B; Neuzil KM; Wright PF
Vaccine; 2000 Sep; 19(2-3):217-26. PubMed ID: 10930676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
